|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FCRL5 |
Gene summary for FCRL5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FCRL5 | Gene ID | 83416 |
| Gene name | Fc receptor like 5 | |
| Gene Alias | BXMAS1 | |
| Cytomap | 1q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q96RD9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 83416 | FCRL5 | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 2.52e-09 | 8.28e-01 | 0.1479 |
| 83416 | FCRL5 | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 2.22e-03 | 5.26e-01 | 0.1531 |
| 83416 | FCRL5 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 3.50e-02 | 4.14e-01 | 0.1619 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FCRL5 | SNV | Missense_Mutation | rs746634732 | c.679N>T | p.Arg227Cys | p.R227C | Q96RD9 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FCRL5 | SNV | Missense_Mutation | c.1162G>A | p.Glu388Lys | p.E388K | Q96RD9 | protein_coding | tolerated(0.92) | benign(0.304) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| FCRL5 | SNV | Missense_Mutation | rs376321602 | c.1694G>C | p.Arg565Pro | p.R565P | Q96RD9 | protein_coding | deleterious(0.02) | possibly_damaging(0.828) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FCRL5 | SNV | Missense_Mutation | c.1516N>G | p.Gln506Glu | p.Q506E | Q96RD9 | protein_coding | deleterious(0.04) | possibly_damaging(0.497) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD | |
| FCRL5 | SNV | Missense_Mutation | c.1162N>A | p.Glu388Lys | p.E388K | Q96RD9 | protein_coding | tolerated(0.92) | benign(0.304) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FCRL5 | SNV | Missense_Mutation | c.843N>C | p.Gln281His | p.Q281H | Q96RD9 | protein_coding | tolerated(0.06) | probably_damaging(0.932) | TCGA-OL-A5DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FCRL5 | insertion | Frame_Shift_Ins | novel | c.2361dupT | p.His788SerfsTer2 | p.H788Sfs*2 | Q96RD9 | protein_coding | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| FCRL5 | SNV | Missense_Mutation | novel | c.2092G>A | p.Val698Ile | p.V698I | Q96RD9 | protein_coding | tolerated(0.09) | possibly_damaging(0.888) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FCRL5 | SNV | Missense_Mutation | c.2524N>A | p.Ala842Thr | p.A842T | Q96RD9 | protein_coding | tolerated(0.06) | benign(0.043) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
| FCRL5 | SNV | Missense_Mutation | c.1999A>T | p.Arg667Trp | p.R667W | Q96RD9 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |